NASDAQ · SRZN
Surrozen, Inc.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
Loading market information…
OTC · VINC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vincerx Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vincerx Pharma, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$8.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vincerx Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q2 2023 | Aug 7, 2023 | -$10.40+20.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
$4.20+$0.17 (+4.22%)
P3 Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.13% below the high.
₪0.01₪0.00 (0.0%)
Purple Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 41.18% below the high.
$1.97-$0.07 (-3.43%)
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.95% below the high.
$0.84-$0.03 (-3.84%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
$3.75+$0.03 (+0.81%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.76% below the high.
$0.06-$0.03 (-33.33%)
FOXO Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.17% below the high.
$0.14-$0.01 (-7.11%)
Silexion Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.59% below the high.
